NCT05043259 - Heterologous Prime-boost Immunization with an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming with an Inactivated SARS-CoV-2 Vaccine | Biotech Hunter

Enrollment

423

Participants

Timeline

Start Date

August 14, 2021

Primary Completion Date

November 1, 2021

Study Completion Date

October 31, 2022

Conditions

COVID-19

Interventions

BIOLOGICAL

inactive SARS-CoV-2 vaccine (Vero cell)

This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.

BIOLOGICAL

Low dose aerosolized Ad5-nCoV

This vaccine is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.1 ml / dose, contains 1×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.

BIOLOGICAL

High dose aerosolized Ad5-nCoV

This vaccine is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.2 ml / dose, contains 2×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.

Trial Locations (1)

Unknown

Donghai County Center for Diseases Control and Prevention, Lianyungang

All Listed Sponsors

lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK